DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Bispecific Antibody Market & Clinical Pipeline Insight 2020" drug pipelines to their offering.
With revolutionization in the medicinal sector and more of inclination towards personalized therapy, the medical world is also witnessing the emergence of advanced analogues of monoclonal antibodies called as Bispecific monoclonal antibodies. As the name signifies the molecules possess dual specificity.
The licensing of the first monoclonal antibody for clinical use dates back to 1986. Since then, almost 70 therapeutic monoclonal antibodies (MAbs) have been approved throughout the world, along with several antibody-related products (e.g., Fc-fusion proteins) making MAbs and related products a dominant component of the biopharmaceutical market, generating revenues of several billion dollars.
Global Bispecific Antibody Market & Clinical Pipeline Insight 2020 Report Highlights:
- Overview of Bispecific Antibody
- Mechanism of Action of Bispecific Antibody
- Design & Engineering of Bispecific Antibodies
- Applications of Bispecific Antibodies
- Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase
- Global Bispecific Antibodies Clinical Pipeline: 123 Bispecific Antibodies
- Marketed Bispecific Antibodies: Blinatumomab (Blincyto) & Catumaxomab (Removab)
Companies Mentioned:
- Ablynx
- Adimab
- Affimed Therapeutics
- Amgen
- AstraZeneca (MedImmune)
- Chugai Pharmaceutical
- Eli Lilly
- EMD Serono
- Emergent BioSolutions
- Genentech
- Genmab
- Immunomedics
- Jounce Therapeutics
- MacroGenics
- Merus
- Neovii Biotech
- NovImmune SA
- OncoMed Pharmaceuticals
- Pieris
- Regeneron Pharmaceuticals
- Roche
-
Sanofi
Report Structure:
1. History of Monoclonal Antibodies
2. Overview of Bispecific Monoclonal Antibody
3. Mechanism of Action of Bispecific Antibody
4. The Design & Engineering of Bispecific Antibodies
5. Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies
6. Applications of Bispecific Antibodies
7. Global Bispecific Antibody Market Overview
8. Global Bispecific Antibody Market Dynamics
9. Global Bispecific Antibody Market Future Prospects
10. Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase
11. Marketed Bispecific Antibodies Clinical Insight
12. Discontinued & Suspended Bispecific Antibodies in Clinical Pipeline by Company, Indication & Phase
13. Competitive Landscape
For more information visit http://www.researchandmarkets.com/research/3s8q6m/global_bispecific
